MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

NCT00797667 ↗

Phase 2 Terminated 660 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.

Timeline

Start: 2008-11-12
Primary completion: 2009-05-20
Completion: 2009-05-20

Outcome

Outcome not reported

Stopped: “The study was terminated based on a recommendation of the DSMB following the identification of two patients with significant elevations in serum transaminases”

Publications

Results Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, Fan X, Lines C, Edvinsson L, Goadsby PJ, Michelson D. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014 Sep 9;83(11):958-66. doi: 10.1212/WNL.0000000000000771. Epub 2014 Aug 8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Telcagepant	Small molecule	140 mg	Oral
Subject	Telcagepant	Small molecule	280 mg	Oral